Shared perspectives on the role of continued therapy in patients with transplant-ineligible newly diagnosed multiple myeloma in light of clinical data and dose adjustment strategies.
Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma
More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.
Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
FDA Grants Orphan Drug Designation to GPRC5D Target in Multiple Myeloma
SAR446523 is currently being evaluated in a first-in-human, phase 1 trial in patients with pretreated relapsed/refractory multiple myeloma.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Isatuximab Combo Approved in the EU for Transplant-Eligible NDMM
Results from the phase 3 GMMG HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.
Belantamab Mafodotin Combos Receive EU Approval for R/R Multiple Myeloma
Phase 3 DREAMM-7 and DREAMM-8 trial results showed that combinations with belantamab mafodotin showed superior efficacy vs standard of care in the disease.